Efpeglenatide: Research Status and Trial Data

Registered trials	5

What efpeglenatide is

Efpeglenatide is an investigational compound that does not have an approved drug label. No regulatory agency has authorized it for medical use, and there are no approved indications, dosing guidelines, or brand names associated with it. Information here reflects registered clinical research only.

Trial footprint

Five trials involving efpeglenatide are registered. Among the sample of studies available, several reached phase 3 testing in people with type 2 diabetes mellitus whose condition was inadequately controlled with metformin alone, with metformin plus a sulfonylurea, or with diet and exercise. One such trial compared efpeglenatide against placebo in patients on metformin with or without a sulfonylurea and was terminated. A related phase 3 trial compared efpeglenatide against dulaglutide in patients on metformin and was also terminated. A separate phase 3 trial comparing efpeglenatide against placebo in patients managed with diet and exercise reached completed status. These records describe trial design and status only, not outcomes or efficacy conclusions.

FAQ

Is efpeglenatide FDA approved?

No. Efpeglenatide is an investigational compound and does not have an approved drug label. There are no approved indications or authorized uses.

What has efpeglenatide been studied for?

Registered trials have evaluated efpeglenatide in people with type 2 diabetes mellitus whose condition was not adequately controlled with metformin, with metformin and a sulfonylurea, or with diet and exercise alone. These studies compared it against placebo or against another compound, dulaglutide.

How many clinical trials have studied efpeglenatide?

Five trials involving efpeglenatide are registered in clinical trial databases. Some of these reached phase 3 testing, though not all were completed.

Were the phase 3 trials of efpeglenatide completed?

Results varied by trial. At least one phase 3 trial comparing efpeglenatide to placebo reached completed status, while two other phase 3 trials, one against placebo and one against dulaglutide, were terminated.

This page is an editorial information resource. It does not sell, prescribe, or recommend any medication. Content is editorial information, not medical advice. Talk to your doctor before any treatment decision.

Sources: ClinicalTrials.gov registry data

Updated 2026-11-07